Company
Sutro
Next Generation Cancer Therapeutics
Also known as Sutro Biopharma, Inc.
- Status
- Operatingas of 2026-09-20
- Business model
- B2B
- Headquarters
- South San Francisco, California, United States
- Legal name
- Sutro Biopharma, Inc.
- sutrobio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Sutro is advancing a next-generation antibody-drug conjugate platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer.
Funding snapshot
- Total raised
- $85.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $85.4M2018-05-24
Funding rounds
- Round, 2018
- $85.4M2018-05-24, SEC form D sold, 15 investors
Loading relationship preview